Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 13,620 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer
Interventions: LCL161, paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 9 more

Conditions: Melanoma
Interventions: GSK1120212, Chemotherapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 13
States / cities: Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more

Conditions: Prurigo Nodularis
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Arkansas City, Arkansas • Los Angeles, California + 13 more

Conditions: Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Immune Checkpoint Inhibitor; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Connective Tissue Disease, Dissecting Aneurysm, Ehlers Danlos Syndrome, Marfan Syndrome, Nail Patella Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Breast Cancer
Interventions: MSI-1436C; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more

Conditions: Sjogren-Larsson Syndrome (SLS)
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Omaha, Nebraska • Pittsburgh, Pennsylvania

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: wild-type reovirus; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Tamoxifen, Palbociclib; Drug
Lead sponsor: Shannon Puhalla; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Neoplasms
Interventions: 9 Peptides from Her-2/neu, CEA, & CTA; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Skin Cancer
Interventions: Part 1: Interview + Questionnaires, Part 2: Multiple Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Arm 1 Daily Boost of Radiation Therapy, Arm 2 Weekly Boost of Radiation Therapy; Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Cognitive Assessment, Palbociclib, Quality-of-Life Assessment, Trastuzumab; Procedure · Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Lake Forest, Illinois • Houston, Texas

Conditions: Venous Leg Ulcer
Interventions: 0.1% TR 987, Placebo gel; Drug
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 9
States / cities: Los Angeles, California • North Miami Beach, Florida • Pembroke Pines, Florida + 6 more

Conditions: Breast Cancer, Cardiac Toxicity
Interventions: management of therapy complications; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 105
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 129
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 110 more

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Breast Cancer, Postoperative Pain, Opioid Use, Local Anesthesia
Interventions: Pectoral Nerve Block, Surgery without Nerve Block; Procedure
Lead sponsor: Main Line Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: No intervention; Other
Lead sponsor: 23andMe, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Obesity
Interventions: Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cutaneous Leishmaniasis
Interventions: Sodium stibogluconate (Pentostam), ThermoMed; Drug · Device
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Colorectal Cancer, Breast Cancer, Coronary Heart Disease, Diabetes
Interventions: Intervention; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6,075 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Study of Heritable Connective Tissue Disorders

Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers

Viral Therapy in Treating Patients With Metastatic Melanoma

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems

Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus

PECS Block in Partial Mastectomy for Postoperative Pain Control

23andMe IPF Research Study

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care